CADTH has published new evidence and guidance on the issue of emergency department (ED) overcrowding. The guidance comes as EDs in Canada continue coping with persistently higher patient volumes, staffing shortages and burnout, and as they brace for a potential influx of visits during respiratory…
It’s been 1 year since CADTH launched the Post-Market Drug Evaluation (PMDE) Program to provide decision-makers with evidence about drugs that have been approved and are already in use by people in Canada. With the PMDE program, CADTH is enhancing how we evaluate drugs across their life cycle and…
World Evidence-Based Healthcare Day October 20, 2023
Today is World Evidence-Based Healthcare Day, a global initiative to raise awareness about the need for better evidence to inform decision-making and improve health outcomes. This year’s theme is Evidence and Global Health Equity. CADTH is proud…
Save the Date!
Join Canadian and international health technology experts from Wednesday, September 4 to Friday, September 6, 2024, for the return of the CADTH Symposium.
The 2024 Symposium will be a 3-day hybrid event with both in-person and virtual attendance options. The in-person program will…
CADTH has appointed new members to its 3 expert review committees: the Canadian Drug Expert Committee, the pan-Canadian Oncology Drug Review Expert Review Committee, and the Health Technology Expert Review Panel. CADTH has also appointed new members to its Post-Market Drug Evaluation Advisory…
CADTH has introduced a new type of recommendation. Time-limited drug reimbursement recommendations are a new recommendation category that will aim to help provide earlier access to promising new treatments that target the unmet needs of people in Canada living with severe, rare, or debilitating…
CADTH is pleased to announce the election of 3 new members to the CADTH Board of Directors.
“On behalf of the Board, I am pleased to welcome Louise Taylor Green, Dr. Jeffrey Tyberg, and Robert Shaffer as directors," said David Agnew, Board Chair. "Each of these remarkable individuals brings unique…
The international collaboration between 6 health technology assessment (HTA) bodies from across the UK, Australia, and Canada welcomes 2 further HTA bodies.
The addition of the Institut national d’excellence en santé et en services sociaux (INESSS) (Quebec) and Pharmac (New Zealand) to the…
CADTH is establishing an industry task force that will build upon the recently released Guidance for Reporting Real-World Evidence to provide advice on the use of industry-generated real-world data (RWD) in its Post-Market Drug Evaluation (PMDE) Program. We are inviting industry representatives to…
A message from Suzanne McGurn, President and CEO, CADTH
On behalf of CADTH and our Board of Directors, I’m pleased to share the CADTH Annual Report for 2022–2023.
The theme of this year’s report, Ahead of the Curve, aligns with our strategic plan and our efforts to shape a future-ready health…
As CADTH continues along the path of strategic transformation, we’re working hard to align the evidence products we deliver with the priority needs of decision-makers in Canada. As part of this work, CADTH has made the decision to retire Reference Lists as a standard offering in our evidence…
The CADTH Weekly Summary is an email newsletter sent every Thursday to bring subscribers important notifications about CADTH drug reimbursement reviews, including input and feedback opportunities, the publication of draft and final drug reimbursement recommendations, and procedural updates.
CADTH…